1. Development of an Intravenously Stable Disulfide-Rich Peptide for the Treatment of Chemotherapy-Induced Neuropathic Pain.
- Author
-
Li T, Tae HS, Chen S, Li X, Liang J, Pan T, Zhang Z, Jiang T, Adams DJ, and Yu R
- Subjects
- Animals, Humans, Receptors, Nicotinic metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Mice, Male, Oxaliplatin pharmacology, Analgesics chemistry, Analgesics pharmacology, Analgesics therapeutic use, Analgesics chemical synthesis, Peptides chemistry, Peptides pharmacology, Peptides therapeutic use, Hyperalgesia drug therapy, Hyperalgesia chemically induced, Administration, Intravenous, Neuralgia drug therapy, Neuralgia chemically induced, Conotoxins chemistry, Conotoxins pharmacology, Disulfides chemistry, Disulfides pharmacology
- Abstract
α-conotoxins (α-Ctxs), a class of disulfide-rich conopetides, are excellent drug leads due to their small size, high selectivity, and potency for specific membrane receptors and ion channels involved in pain transmission. However, their high susceptibility to proteolytic degradation limits their therapeutic potential. In this study, we designed and synthesized a series of conformationally stable analogues of α-Ctx Mr1.1[S4Dap] using various structural optimization strategies. The Mr1.1[S4Dap, C16Pen] analogue maintained potency at human α9α10 nicotinic acetylcholine receptors, with a half-maximal inhibitory concentration (IC
50 ) of 4 nM. It exhibited over a 5-fold increase in serum stability compared to Mr1.1[S4Dap], without disrupting its overall conformation. Furthermore, intravenous application of Mr1.1[S4Dap, C16Pen] showed potent analgesic activity in oxaliplatin-induced cold allodynia, indicating a high potential for drug development. Overall, the results from this study provide valuable insights for optimizing the serum stability of disulfide-rich peptides in future therapeutic applications.- Published
- 2024
- Full Text
- View/download PDF